CNTX
Context Therapeutics Inc

5,234
Mkt Cap
$209.48M
Volume
2.41M
52W High
$2.85
52W Low
$0.49
PE Ratio
-8.15
CNTX Fundamentals
Price
$2.17
Prev Close
$2.28
Open
$2.26
50D MA
$1.51
Beta
1.05
Avg. Volume
2.68M
EPS (Annual)
-$0.4575
P/B
2.86
Rev/Employee
$0.00
Loading...
Loading...
News
all
press releases
Context Therapeutics (NASDAQ:CNTX) Lowered to Sell Rating by Wall Street Zen
Wall Street Zen lowered Context Therapeutics from a "hold" rating to a "sell" rating in a research report on Sunday...
MarketBeat·2d ago
News Placeholder
More News
News Placeholder
Context Therapeutics Inc. (NASDAQ:CNTX) Receives Average Recommendation of "Moderate Buy" from Analysts
Shares of Context Therapeutics Inc. (NASDAQ:CNTX - Get Free Report) have been assigned an average recommendation of "Moderate Buy" from the eight research firms that are presently covering the firm...
MarketBeat·4d ago
News Placeholder
Context Therapeutics (NASDAQ:CNTX) Upgraded to Hold at Wall Street Zen
Wall Street Zen raised Context Therapeutics from a "sell" rating to a "hold" rating in a research report on Saturday...
MarketBeat·10d ago
News Placeholder
Context Therapeutics (NASDAQ:CNTX) Coverage Initiated by Analysts at Jones Trading
Jones Trading initiated coverage on Context Therapeutics in a research report on Monday. They issued a "buy" rating and a $7.00 price objective for the company...
MarketBeat·2mo ago
News Placeholder
Context Therapeutics Inc. (NASDAQ:CNTX) Given Average Recommendation of "Moderate Buy" by Brokerages
Context Therapeutics Inc. (NASDAQ:CNTX - Get Free Report) has received an average recommendation of "Moderate Buy" from the nine brokerages that are covering the stock, Marketbeat.com reports. One...
MarketBeat·3mo ago
News Placeholder
Context Therapeutics (NASDAQ:CNTX) Upgraded to "Sell" at Wall Street Zen
Wall Street Zen upgraded Context Therapeutics to a "sell" rating in a report on Saturday...
MarketBeat·3mo ago
News Placeholder
Context Therapeutics (NASDAQ:CNTX) Earns "Buy" Rating from D. Boral Capital
D. Boral Capital reiterated a "buy" rating and issued a $9.00 target price on shares of Context Therapeutics in a research report on Thursday...
MarketBeat·3mo ago
News Placeholder
Context Therapeutics (NASDAQ:CNTX) Announces Earnings Results
Context Therapeutics (NASDAQ:CNTX - Get Free Report) posted its quarterly earnings data on Wednesday. The company reported ($0.10) earnings per share (EPS) for the quarter, missing analysts...
MarketBeat·3mo ago
News Placeholder
Context Therapeutics Stock Jumps Pre-Market On Analyst's Near 4x Upside View: Retail Pins High Hopes Too
The micro-cap biotech is building a portfolio of in-licensed clinical-stage TCE bispecific antibodies, which JMP described as "innovative”
Stocktwits·1y ago
<
...
1
>

Latest CNTX News

View
Top Discussions

Advertisement|Remove ads.

Advertisement|Remove ads.